BIIB NASDAQ
Biogen Inc.
1W: +4.0%
1M: +10.5%
3M: +20.8%
YTD: +42.1%
1Y: +68.6%
3Y: -1.8%
5Y: -5.7%
$252.73
+0.47 (+0.19%)
Weekly Expected Move ±4.4%
$229
$240
$251
$262
$273
Credit Risk of going bust: lower than 68% of companies Debt: 18.3% of company value Bonds: $137.0M held by 192 funds, 91 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $4.22 (down 98%), Biogen Inc. would be worth roughly what it owes.
Total debt $8.36B against a stock market value of $37.34B.
Distance to default 7.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.45B (short-term plus half of long-term), stock volatility 33.9%; Altman Z 3.16. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $4.22 (down 98%), Biogen Inc. would be worth roughly what it owes.
Total debt $8.36B against a stock market value of $37.34B.
Distance to default 7.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.45B (short-term plus half of long-term), stock volatility 33.9%; Altman Z 3.16. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships5
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2023-07-31
Earliest Filing
2026-03-31
Latest Filing
target: 3
acquirer: 2
Counterparties (Filed by BIIB)
5 relationshipsCompanies named in BIIB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | target | Target company in a merger agreement to be acquired by Biogen via a tender offer. | 2026-03-31 | View |
| Aspen Purchaser Sub, Inc. | ASPU | acquirer | Wholly owned subsidiary of Biogen acting as the purchaser in the merger agreement. | 2026-03-31 | View |
| Reata Pharmaceuticals, Inc. | — | target | Target company in the acquisition by Biogen Inc. | 2023-09-01 | View |
| River Acquisition, Inc. | — | acquirer | Wholly-owned subsidiary of Biogen entering into a merger agreement with Reata. | 2023-07-31 | View |
| Reata Pharmaceuticals, Inc. | — | target | Target company to be merged with Biogen's subsidiary, with stock converted to cash. | 2023-07-31 | View |
Mentioned As Counterparty
1 mentionsOther companies that named BIIB in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-29 | Earnings Release; Exhibits | View | |
| 2026-07-01 | Earnings Release | View | |
| 2026-06-10 | Shareholder Vote | View | |
| 2026-06-10 | Exhibits | View | |
| 2026-05-14 | Material Agreement; Acquisition/Disposition; Financial Obligation; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-04-29 | Earnings Release; Exhibits | View | |
| 2026-04-06 | Earnings Release | View | |
| 2026-03-31 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-03-11 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-11 | Departure/Election of Directors; Appointment of Officers; Other Events | View | |
| 2026-02-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-14 | Results of Operations and Financial Condition | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-23 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR